well, we knew it was coming and here it is. at least they took some of the sting away with the uplist news. gonna let the smoke clear and possibly take a position. im a little spread out at the moment, so il have to wait and see. market timing can be a cruel mistress
Mapp Pharma had a drug for migraines. They were "taken out" at $25.00 per share a few months back. Their drug was a re-formulation of an existing drug. I am not certain, but I think the valuation at the time of the sale was around 1Bil. TNXP has a very similar strategy. It is a bio-tech, so it is risky. What I like is that they have the cash to get through the phase III trial. I think this is a very good story.
You nailed it bigfella...with regard to market timing, the good thing about a bio-tech is the fact that it really should be "market" neutral. They are event driven. I had a few bio tech stocks that did very well when the market got clobbered in 2008. They continued to perform well for the next several years despite a volatile market. I will be curious to see how much support Roth Capital gives this stock. A few good research reports, conferences and events could push this stock a lot higher. The current valuation is tiny for a company with this much potential. Look at MAPP pharma. I believe they got taken out for close to a 1 Bil market cap. Their drug was also a re-formulation of an existing drug. I also believe this was prior to final phase III results. If TNXP got taken out at a 100MM valuation, I would be a very happy camper. With regard to my "handle", I love dogs as well. I worked for a guy who was a vet who had the nick-name Dogbeater while he was in Korea. He is no longer alive, but he was a great man.
yes that is why i only trade bio stocks. im really more of a long term investor, not a trader. i am familiar with mapp. they were bought out after phase 3 but before fda approval, just under a billion. actually did some dd on the company, but took no position. DOE!